Trials / Unknown
UnknownNCT05684380
Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)
National, Multicenter, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 514 (estimated)
- Sponsor
- EMS · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of MAZ-101 in the treatment of moderate-severe persistent allergic rhinitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MAZ-101association | Experimental drug |
| DRUG | DYMISTA® | Active comparator |
Timeline
- Start date
- 2024-09-01
- Primary completion
- 2024-11-01
- Completion
- 2025-05-01
- First posted
- 2023-01-13
- Last updated
- 2024-02-16
Source: ClinicalTrials.gov record NCT05684380. Inclusion in this directory is not an endorsement.